Advanced search
Publication Cover
Pain Management Volume 2, 2012 - Issue 1
Submit an article Journal homepage
137
Views
0
CrossRef citations to date
0
Altmetric
Management Perspective

Is Morphine Still the Best Reference Opioid?

Rafael GálvezCorrespondence[email protected]
&
Concepción Pérez1 Pain Unit, Hospital de la Princesa, Madrid, Spain
Pages 33-45 | Published online: 21 Dec 2011

References

  • WHO. Cancer Pain Relief with a Guide to Opioid Availability (2nd Edition). WHO Press, Switzerland (1996).
  • Zech DF , GrondS, LynchJ, HertelD, LehmannKA. Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain63(1) , 65–76 (1995).
  • Azevedo São Leão Ferreira K , KimuraM, Jacobsen Teixeira M. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support. Care Cancer14(11) , 1086–1093 (2006).
  • Meuser T , PietruckC, RadbruchL, StuteP, LehmannKA, GrondS. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain93(3) , 247–257 (2001).
  • Hanks GW , ConnoF, ChernyN et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 84(5) , 587–593 (2001).
  • Pergolizzi J , BögerRH, BuddK et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 8(4) , 287–313 (2008).
  • Patt R , LangS. The Complete Guide to Relieving Cancer Pain and Suffering. Oxford University Press, UK (2006).
  • Trescot AM , HelmS, HansenH et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians‘ (ASIPP) guidelines. Pain Physician 11(Suppl. 2) , S5–S62 (2008).
  • University of Wisconsin Pain and Policy Studies Group. Do international model drug control laws provide for drug availability? J. Pain Palliat. Care Pharmacother.23(2) , 145–152 (2009).
  • Lynch T , ClarkD, CentenoC et al. Barriers to the development of palliative care in the countries of Central and Eastern Europe and the Commonwealth of Independent States. J. Pain Symptom Manage. 37(3) , 305–315 (2009).
  • Foley KM , WagnerJL, JoransonDE, GelbandH. Pain control for people with cancer and AIDS. In: Disease Control Priorities in Developing Countries (2nd Edition). Jamison DT, Breman JG, Measham AR et al. (Eds). World Bank, Washington, DC, USA (2006).
  • Cherny NI , BaselgaJ, de Conno F, Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann. Oncol.21(3) , 615–626 (2010).
  • Lynch T , ClarkD, CentenoC et al. Barriers to the development of palliative care in western Europe. Palliat. Med. 24(8) , 812–819 (2010).
  • Cherny NI , CataneR, KosmidisPA. Problems of opioid availability and accessibility across Europe: ESMO tackles the regulatory causes of intolerable and needless suffering. Ann. Oncol.17(6) , 885–887 (2006).
  • Portenoy RK . Treatment of cancer pain. Lancet377(9784) , 2236–2247 (2011).
  • Snidvongs S , MehtaV. Recent advances in opioid prescription for chronic non-cancer pain. Postgrad. Med. J. doi:10.1136/pgmj.2010.112045 (2011) (Epub ahead of print).
  • Tzschentke TM , JahnelU, KögelB et al. Tapentadol hydrochloride: a next generation, centrally acting analgesic with two mechanism of action in a single molecule. Drugs Today 45(7) , 483–496 (2009).
  • Wild JE , GrondS, KuperwasserB et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 10(5) , 416–427 (2010).
  • Afilalo M , EtropolskiM, KuperwasserB et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled Phase III study. Clin. Drug Invest. 30(8) , 489–505 (2010).
  • WHO. Cancer Pain Relief (2nd Edition). WHO Press, Switzerland (1996).
  • Hanks GW , de Conno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. Expert Working Group of European Association of Palliative Care. BMJ312 , 823–826 (1996).
  • Hanks GW , de Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br. J. Cancer84(5) , 587–593 (2001).
  • Apolone G , ManganoS, CompagnoniA et al.; Cancer Pain Outcome Research Study Group (CPOR SG). A multidisciplinary project to improve the quality of cancer pain management in Italy: background, methods, and preliminary results. J. Ambul. Care Manage.29(4) , 332–341 (2006).
  • Garcia del Pozo J , CarvajalA, ViloriaJM et al. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur. J. Clin. Pharmacol. 64(4) , 411–415 (2008).
  • Adams V ; Worldwide Palliative Care Alliance. Access to pain relief: an essential human right. A report for World Hospice and Palliative Care Day 2007. Help the hospices for the Worldwide Palliative Care Alliance. J. Pain Palliat. Care Pharmacother.22(2) , 101–129 (2008).
  • Gaakeer MI , van Lieshout JM, Bierens JJ. Pain management in emergency departments: a review of present protocols in The Netherlands. Eur. J. Emerg. Med.17(5) , 286–289 (2010).
  • Quigley C . Opioids in people with cancer-related pain. Clin. Evid. (Online)PII , 2408 (2008).
  • Mercadante S . Intravenous patient-controlled analgesia and management of pain in post-surgical elderly with cancer. Surg. Oncol.19(3) , 173–177 (2010).
  • Klepstad P , KaasaS, ChernyN, HanksG, De Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat. Med.19(6) , 477–484 (2005).
  • Hamunen K , Laitinen-ParkkonenP, PaakkariP et al. What do different databases tell about the use of opioids in seven European countries in 2002? Eur. J. Pain 12(6) , 705–715 (2008).
  • Smith H , BruckenthalP. Implications of opioid analgesia for medically complicated patients. Drugs Aging27(5) , 417–433 (2010).
  • Wyne A , RaiR, CuerdenM, ClarkWF, SuriRS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin. J. Am. Soc. Nephrol.6(2) , 326–333 (2011).
  • Davison SN . Chronic pain in end-stage renal disease. Adv. Chronic Kidney Dis.12(3) , 326–334 (2005).
  • Nayak-Rao S . Achieving effective pain relief in patients with chronic kidney disease: a review of analgesics in renal failure. J. Nephrol.24(1) , 35–40 (2011).
  • Murtagh FE , ChaiMO, DonohoeP et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J. Pain Palliat. Care Pharmacother. 21(2) , 5–16 (2007).
  • Kahan M , SrivastavaA, WilsonL, Mailis-GagnonA, MidmerD. Opioids for managing chronic non-malignant pain: safe and effective prescribing. Can. Fam. Physician52(9) , 1091–1096 (2006).
  • Hanna M . The effects of liver impairment on opioids used to relieve pain in cancer patients. Palliat. Med.25(5) , 604–605 (2011).
  • Chandok N , WattKD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin. Proc.85(5) , 451–458 (2010).
  • Cherny N , RipamontiC, PereiraJ et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol. 19(9) , 2542–2554 (2001).
  • Mercadante S , BrueraE. Opioid switching: a systematic and critical review. Cancer Treat. Rev.32(4) , 304–315 (2006).
  • Kloke M , RappM, BosseB, KlokeO. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support. Care Cancer8(6) , 479–486 (2000).
  • Quigley C . Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst. Rev.3 , CD004847 (2004).
  • Riley J , RossJR, RutterD et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support. Care Cancer 14(1) , 56–64 (2006).
  • Ross JR , RileyJ, QuigleyC, WelshKI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist11(7) , 765–773 (2006).
  • Mercadante S , FerreraP, VillariP et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J. Pain Symptom Manag. 37(4) , 632–641 (2009).
  • de Stoutz ND , BrueraE, Suarez-AlmazorM. Opioid rotation for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage.10(5) , 378–384 (1995).
  • Benitez-Rosario MA , Salinas-MartinA, Aguirre-JaimeA, Perez-MendezL, FeriaM. Morphine–methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J. Pain Symptom Manage.37(6) , 1061–1068 (2009).
  • Wirz S , WartenbergHC, ElsenC, WittmannM, DiederichsM, NadstawekJ. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial. Clin. J. Pain22(9) , 770–775 (2006).
  • Mercadante S . Opioid rotation for cancer pain: rationale and clinical aspects. Cancer86(9) , 1856–1866 (1999).
  • Narabayashi M , SaijoY, TakenoshitaS et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J. Clin. Oncol. 38(4) , 296–304 (2008).
  • Gammaitoni AR , FineP, AlvarezN, McPhersonML, BergmarkS. Clinical application of opioid equianalgesic data. Clin. J. Pain19(5) , 286–297 (2003).
  • Anderson R , SaiersJH, AbramS, SchlichtC. Accuracy in equianalgesic dosing. Conversion dilemmas. J. Pain Symptom Manage.21(5) , 397–406 (2001).
  • Shaheen PE , WalshD, LasheenW et al. Opioid equianalgesic tables: are they all equally dangerous? J. Pain Symptom Manage. 38(3) , 409–417 (2009).
  • Mercadante S , CaraceniA. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat. Med.25(5) , 504–515 (2011).
  • Caraceni A , MartiniC, ZeccaE et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat. Med. 18(3) , 177–183 (2004).
  • Zeppetella G , O‘DohertyCA, CollinsS. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J. Pain Symptom Manage.20(2) , 87–92 (2000).
  • Zeppetella G . Impact and management of breakthrough pain in cancer. Curr. Opin. Support. Palliat. Care3(1) , 1–6 (2009).
  • Davies AN , DickmanA, ReidC, StevensAM, ZeppetellaG. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur. J. Pain13(4) , 331–338 (2009).
  • Mercadante S , RadbruchL, CaraceniA et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94(3) , 832–839 (2002).
  • Hao J , HengPW. Buccal delivery systems. Drug Dev. Ind. Pharm.29(8) , 821–832 (2003).
  • Zhang H , ZhangJ, StreisandJB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet.41(9) , 661–680 (2002).
  • Stevens RA , GhaziSM. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control7(2) , 132–141 (2000).
  • Mystakidou K , KatsoudaE, ParpaE, VlahosL, TsiatasML. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv.13(4) , 269–276 (2006).
  • Zeppetella G . An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J. Pain Symptom Manage.20(4) , 253–258 (2000).
  • Good P , JacksonK, BrumleyD, AshbyM. Intranasal sufentanil for cancer-associated breakthrough pain. Palliat. Med.23(1) , 54–58 (2009).
  • Gardner-Nix J . Oral transmucosal fentanyl and sufentanil for incident pain. J. Pain Symptom Manage.22(2) , 627–630 (2001).
  • Bruera E , PalmerJL, BosnjakS et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, doubleblind study. J. Clin. Oncol. 1 , 185–192 (2004).
  • Bruera E , SweeneyC. Methadone use in cancer patients with pain: a review. J. Palliat. Med.5(1) , 127–138 (2002).
  • Mercadante S , PorzioG, FerreraP et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur. J. Pain 12(8) , 1040–1046 (2008).
  • Cherny N . Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain? Palliat. Med.25(5) , 488–493 (2011).
  • King SJ , ReidC, ForbesK, HanksG. A systematic review of oxycodone in the management of cancer pain. Palliat. Med.25(5) , 454–470 (2011).
  • Fredheim OM , DaleO, KaasaS, BorchgrevinkPC. Morphine or oxycodone tablets for pain? Tidsskr. Nor. Laegeforen.130(15) , 1479–1481 (2010).
  • Rubino M , SummersKH, PuenpatomA et al. A Comparison of Daily Average Consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. J. Manag. Care Pharm. 17(5) , 367–376 (2011).
  • Berner T , ThomsonH, HartryA et al. A comparison of daily average consumption of oxycodone controlled release (OxyContin CR) and oxymorphone extended release (Opana ER) in patients with low back pain. P T 36(3) , 139–144 (2011).
  • Rothwell MP , PearsonD, HunterJD et al. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study. Br. J. Anaesth. 106(6) , 865–872 (2011).
  • Portenoy RK , FarrarJT, BackonjaMM et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin. J. Pain 23(4) , 287–299 (2007).
  • Muijsers RB , WagstaffAJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs61(15) , 2289–2307 (2001).
  • Grond S , RadbruchL, LehmannKA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin. Pharmacokinet.38(1) , 59–89 (2000).
  • Kornick CA , Santiago-PalmaJ, MorylN, PayneR, ObbensEA. Benefit–risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf.26(13) , 951–973 (2003).
  • Ripamonti C , FagnoniE, CampaT, BrunelliC, De Conno F. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support. Care Cancer.14(5) , 400–407 (2006).
  • Clemens KE , KlaschikE. Clinical experience with transdermal and orally administered opioids in palliative care patients –a retrospective study. Jpn J. Clin. Oncol.37(4) , 302–309 (2007).
  • Tassinari D , DrudiF, RosatiM, MaltoniM. Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review. Palliat. Med.25(5) , 478–487 (2011).
  • Tassinari D , SartoriS, TamburiniE et al. Transdermal fentanyl as a front-line approach to moderate–severe pain: a meta-analysis of randomized clinical trials. Palliat. Care 25(3) , 172–180 (2009).
  • Kress HG . Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur. J. Pain13 , 219–230 (2009).
  • Huang P , KehnerGB, CowanA et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297 , 688–695 (2001).
  • Vadivelu N , HinesRL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin. Interv. Aging3(3) , 421–430 (2008).
  • Deandrea S , CorliO, MoschettiI et al. Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther. Clin. Risk Manag. 5(5) , 707–718 (2009).
  • Pergolizzi J , AloisiAM, DahanA et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 10(5) , 428–450 (2010).
  • Quigley C . Hydromorphone for acute and chronic pain. Cochrane Database Syst. Rev.1 , CD003447 (2002).
  • Pigni A , BrunelliC, CaraceniA. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat. Med.25(5) , 471–477 (2011).
  • Wiffen PJ , McQuayHJ. Oral morphine for cancer pain. Cochrane Database Syst. Rev.4 , CD003868 (2007).
  • Caraceni A , PigniA, BrunelliC. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat. Med.25(5) , 402–409 (2011).
  • Bekkering GE , Soares-WeiserK, ReidK et al. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. Curr. Med. Res. Opin. 27(7) , 1477–1491 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.